ADIPOQ and metabolic dysfunction-associated steatohepatitis: A 2010 systematic review with meta‐analysis on this issue evidenced a statistically significant decrease in adiponectin serum levels in patients with NASH in comparison with healthy control or fatty liver subjects.72